SKIL抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Huvec cells, Primary antibody: P01824(SKIL Antibody) at dilution 1/450, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P01824(SKIL Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P01824(SKIL Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

SKIL (Ski-like) antibody is used to detect the SKIL protein, a member of the Ski family of transcriptional regulators involved in modulating transforming growth factor-beta (TGF-β) signaling pathways. SKIL, also known as SnoN, plays a dual role in cellular processes, acting as both a co-repressor and co-activator depending on cellular context. It interacts with Smad proteins, key mediators of TGF-β signaling, to regulate gene expression linked to cell proliferation, differentiation, apoptosis, and epithelial-mesenchymal transition (EMT). Dysregulation of SKIL has been implicated in cancer progression, fibrosis, and developmental disorders, as aberrant TGF-β signaling can promote tumor metastasis or suppress immune responses.

The SKIL antibody is valuable in research to assess protein expression levels in tissues or cell lines, particularly in studies exploring cancer biology, tissue remodeling, or TGF-β pathway mechanisms. Its application spans immunohistochemistry, Western blotting, and immunofluorescence, aiding in the identification of SKIL's role in diseases. For example, elevated SKIL expression has been observed in certain cancers (e.g., breast, lung), correlating with poor prognosis. Conversely, reduced levels may indicate impaired TGF-β regulation. Researchers also use SKIL antibodies to investigate post-translational modifications, such as ubiquitination, which regulates its stability and activity. Understanding SKIL dynamics provides insights into therapeutic targeting of TGF-β-associated pathologies.